G72 primate-specific gene: A still enigmatic element in psychiatric disorders

Cellular and Molecular Life Sciences

Volumn 73, Issue 10, 2016, Pages 2029-2039

  Sacchi, Silvia ^a   Binelli, Giorgio ^a   Pollegioni, Loredano ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

d Serine; DAOA; Molecular basis; NMDA receptors; pLG72; Schizophrenia

Indexed keywords

DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE ACTIVATOR; PLG72 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; DAOA PROTEIN, HUMAN; RECOMBINANT PROTEIN;

G72 GENE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; MENTAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; BIPOLAR DISORDER; CHROMOSOME 13; GENE EXPRESSION REGULATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ANIMALS; BIPOLAR DISORDER; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 13; GENE EXPRESSION REGULATION; GENETIC LINKAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; MICE; MICE, TRANSGENIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; PSYCHOTIC DISORDERS; RECOMBINANT PROTEINS; SCHIZOPHRENIA;

EID: 84989794455     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2165-6     Document Type: Review

References (64)

1. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H et al (2002) Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99:13675-13680
2. Schultz CC, Nenadic I, Koch K, Wagner G, Roebel M, Schachtzabel C et al (2011) Reduced cortical thickness is associated with the glutamatergic regulatory gene risk variant DAOA Arg30Lys in schizophrenia. Neuropsychopharmacology 36:1747-1753
3. Donohoe G, Morris DW, Robertson IH, McGhee KA, Murphy K, Kenny N et al (2007) DAOA ARG30LYS and verbal memory function in schizophrenia. Mol Psychiatry 12:795-796
4. Sullivan PF (2012) Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat Med 18:210-212
5. Sacchi S, Caldinelli L, Cappelletti P, Pollegioni L, Molla G (2012) Structure-function relationships in human d-amino acid oxidase. Amino Acids 43:1833-1850
6. Pollegioni L, Sacchi S (2010) Metabolism of the neuromodulator d-serine. Cell Mol Life Sci 67:2387-2404
7. Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD et al (2000) d-serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 97:4926-4931
8. Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA et al (2006) Glia-derived d-serine controls NMDA receptor activity and synaptic memory. Cell 125:775-784
9. Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M et al (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633-646
10. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39
11. Bear MF, Malenka RC (1994) Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 4:389-399
12. Kvajo M, Dhilla A, Swor DE, Karayiorgou M, Gogos JA (2008) Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 13:685-696
13. Hattori E, Liu C, Badner JA, Bonner TI, Christian SL, Maheshwari M et al (2003) Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 72:1131-1140
14. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D et al (2004) Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 56:169-176
15. Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R et al (2014) Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Mol Psychiatry 19:636-637
16. Sacchi S, Bernasconi M, Martineau M, Mothet JP, Ruzzene M, Pilone MS et al (2008) pLG72 modulates intracellular d-serine levels through its interaction with d-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem 283:22244-22256
17. Benzel I, Kew JN, Viknaraja R, Kelly F, de Belleroche J, Hirsch S et al (2008) Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry 8:94-107
18. FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest AR, Kawaji H, Rehli M, Baillie JK, de Hoon MJ et al (2014) A promoter-level mammalian expression atlas. Nature 507:462-470
19. Lappalainen T, Sammeth M, Friedländer MR, 't Hoen PA, Monlong J, Rivas MA et al (2013) Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501:506-511
20. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S et al (2013) The Genotype-Tissue Expression (GTEx) project. Nat Genet 45:580-585
21. Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET et al (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348:648-660
22. Molla G, Bernasconi M, Sacchi S, Pilone MS, Pollegioni L (2006) Expression in Escherichia coli and in vitro refolding of the human protein pLG72. Protein Expr Purif 46:150-155
23. Pollegioni L, Piubelli L, Sacchi S, Pilone MS, Molla G (2007) Physiological functions of d-amino acid oxidases: from yeast to humans. Cell Mol Life Sci 64:1373-1394
24. Caldinelli L, Molla G, Bracci L, Lelli B, Pileri S, Cappelletti P et al (2010) Effect of ligand binding on human d-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Protein Sci 19:1500-1512
25. Katane M, Kawata T, Nakayama K, Saitoh Y, Kaneko Y, Matsuda S et al (2015) Characterization of the enzymatic and structural properties of human d-aspartate oxidase and comparison with those of the rat and mouse enzymes. Biol Pharm Bull 38:298-305
26. Sacchi S, Cappelletti P, Giovannardi S, Pollegioni L (2011) Evidence for the interaction of d-amino acid oxidase with pLG72 in a glial cell line. Mol Cell Neurosci 48:20-28
27. Cappelletti P, Campomenosi P, Pollegioni L, Sacchi S (2014) The degradation (by distinct pathways) of human d-amino acid oxidase and its interacting partner pLG72 - two key proteins in d-serine catabolism in the brain. FEBS J 281:708-723
28. Otte DM, Raskó T, Wang M, Dreiseidler M, Drews E, Schrage H, Wojtalla A, Höhfeld J, Wanker E, Zimmer A (2014) Identification of the mitochondrial MSRB2 as a binding partner of LG72. Cell Mol Neurobiol 34:1123-1130
29. Wang M, Chen H-J, Zhang J, Li W, Xie X, Chang H-T (2015) Identification of pLG72-induced oxidative stress using systemic approaches. BioMed Res Int (Article ID 429253)
30. Korde AS, Maragos WF (2012) Identification of an N-methyl-d-aspartate receptor in isolated nervous system mitochondria. J Biol Chem 287:35192-35200
31. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P et al (2014) A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506:185-190
32. Otte DM, Bilkei-Gorzó A, Filiou MD, Turck CW, Yilmaz O, Holst MI et al (2009) Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 19:339-348
33. Cheng L, Hattori E, Nakajima A, Woehrle NS, Opal MD, Zhang C et al (2014) Expression of the G72/G30 gene in transgenic mice induces behavioral changes. Mol Psychiatry 19:175-183
34. Filiou MD, Teplytska L, Otte DM, Zimmer A, Turck CW (2012) Myelination and oxidative stress alterations in the cerebellum of the G72/G30 transgenic schizophrenia mouse model. J Psychiatr Res 46:1359-1365
35. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798-805
36. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyás E, Eberlin MN et al (2009) Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43:978-986
37. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S et al (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44:1176-1189
38. Wood PL, Filiou MD, Otte DM, Zimmer A, Turck CW (2014) Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse. Schizophr Res 159:365-369
39. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B et al (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378-1385
40. Hambsch B, Keyworth H, Lind J, Otte DM, Racz I, Kitchen I et al (2014) Chronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia. Br J Pharmacol 171:1758-1771
41. Otte DM, Sommersberg B, Kudin A, Guerrero C, Albayram O, Filiou MD et al (2011) N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 36:2233-2243
42. Goldberg TE, Straub RE, Callicott JH, Hariri A, Mattay VS, Bigelow L et al (2006) The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 31:2022-2032
43. Detera-Wadleigh SD, McMahon FJ (2006) G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 60:106-114
44. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ et al (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40:827-834
45. Mössner R, Schuhmacher A, Wagner M, Quednow BB, Frommann I, Kühn KU et al (2010) DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. Eur Arch Psychiatry Clin Neurosci 260:209-225
46. Schizophrenia Psychiatric Genome-Wide Association Study Consortium (2011) Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43:969-976
47. Sullivan PF, Daly MJ, O'Donovan M (2012) Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 13:537-551
48. Schizophrenia working group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421-427
49. Hall J, Whalley HC, Moorhead TW, Baig BJ, McIntosh AM, Job DE et al (2008) Genetic variation in the DAOA (G72) gene modulates hippocampal function in subjects at high risk of schizophrenia. Biol Psychiatry 64:428-433
50. Krug A, Markov V, Krach S, Jansen A, Zerres K, Eggermann T et al (2011) Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals. Hum Brain Mapp 32:118-126
51. Andreasen NC, Calarge CA, O'Leary DS (2008) Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. Schizophr Bull 34:708-719
52. Brüne M, Ozgürdal S, Ansorge N, von Reventlow HG, Peters S, Nicolas V et al (2011) An fMRI study of "theory of mind" in at-risk states of psychosis: comparison with manifest schizophrenia and healthy controls. Neuroimage 55:329-337
53. Hartz SM, Ho BC, Andreasen NC, Librant A, Rudd D, Epping EA et al (2010) G72 influences longitudinal change in frontal lobe volume in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 153B:640-647
54. Li D, He L (2007) G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 175:917-922
55. Nickl-Jockschat T, Stöcker T, Krug A, Markov V, Maximov II, Huang R et al (2015) Genetic variation in the G72 gene is associated with increased frontotemporal fiber tract integrity. Eur Arch Psychiatry Clin Neurosci 265:291-301
56. Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S et al (2015) Imaging genetics and psychiatric disorders. Curr Mol Med 15:168-175
57. Sumner JA, Powers A, Jovanovic T, Koenen K (2015) Genetic influences on the neural and physiological bases of acute threat: a research domain criteria (RDoC) perspective. Am J Med Genet Part B Neuropsychiatr.1718:44-64 doi: 10.1002/ajmg.b.32384
58. Medland SE, Jahanshad N, Neale BM, Thompson PM (2014) Whole-genome analyses of whole-brain data: working within an expanded search space. Nat Neurosci 17:791-800
59. International Schizophrenia Consortium (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752
60. Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T et al (2009) Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 18:988-996
61. Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A et al (2011) Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471:499-503
62. Weiss KM (2008) Tilting at Quixotic Trait Loci (QTL): an evolutionary perspective on genetic causation. Genetics 179:1741-1756
63. Sacchi S, Rosini E, Pollegioni L, Molla G (2013) d-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des 19:2499-2511
64. Terry-Lorenzo RT, Masuda K, Sugao K, Fang QK, Orsini MA, Sacchi S et al (2015) High-throughput screening strategy identifies allosteric, covalent human d-amino acid oxidase inhibitor. J Biomol Screen 20:1218-1231